Sartor R Balfour
Department of Medicine, Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599-7038, USA.
Curr Opin Gastroenterol. 2003 Jul;19(4):358-65. doi: 10.1097/00001574-200307000-00006.
This review discusses the role of bacterial adjuvants and antigens in induction and reactivation of chronic intestinal inflammation in susceptible hosts; discusses the results of recent therapeutic trials of antibiotics, probiotics, and prebiotics; and suggests future treatment strategies.
Bacterial adjuvants, including peptidoglycan, lipopolysaccharide, and DNA (CpG) bind to membrane-bound toll-like receptors (TLR-2, 4, and 9. respectively) or cytoplasmic (NOD1 and NOD2) receptors (pattern recognition receptors) that activate nuclear factor-kappaB and transcription of many proinflammatory cytokines and adhesion, costimulatory, and major histocompatibility complex class II molecules. Experimental enterocolitis does not occur in a sterile (germ-free) environment and is prevented and treated by broad-spectrum antibiotics. Individual nonpathogenic intestinal bacterial species selectively induce experimental colitis, with host specificity. Crohn disease and ulcerative colitis patients exhibit pathogenic immune responses (loss of immunologic tolerance) to multiple normal enteric bacterial species and serologic responses to Mycobacterium paratuberculosis. Metronidazole and ciprofloxacin selectively treat colonic Crohn disease, but not ulcerative colitis or ileal Crohn disease, and may prevent recurrence of postoperative Crohn disease. Certain probiotic species decrease relapse of ulcerative colitis and chronic pouchitis and delay onset of pouchitis.
Normal, nonpathogenic enteric bacteria induce and perpetuate chronic intestinal inflammation in genetically susceptible hosts with defective immunoregulation, bacterial clearance, or mucosal barrier function. Altering the composition and decreasing mucosal adherence/invasion of commensal bacteria with antibiotics, probiotics, and prebiotics can potentially prevent and treat Crohn disease, pouchitis, and possibly ulcerative colitis, but optimal treatments have not yet been identified.
本综述探讨细菌佐剂和抗原在易感宿主慢性肠道炎症的诱导和再激活中的作用;讨论抗生素、益生菌和益生元近期治疗试验的结果;并提出未来的治疗策略。
细菌佐剂,包括肽聚糖、脂多糖和DNA(CpG),分别与膜结合的Toll样受体(TLR-2、4和9)或细胞质(NOD1和NOD2)受体(模式识别受体)结合,这些受体激活核因子-κB以及许多促炎细胞因子和黏附、共刺激和主要组织相容性复合体II类分子的转录。实验性小肠结肠炎不会在无菌(无特定病原体)环境中发生,并且可通过广谱抗生素预防和治疗。个别非致病性肠道细菌种类具有宿主特异性地选择性诱导实验性结肠炎。克罗恩病和溃疡性结肠炎患者对多种正常肠道细菌种类表现出致病性免疫反应(免疫耐受性丧失),并对副结核分枝杆菌产生血清学反应。甲硝唑和环丙沙星选择性治疗结肠克罗恩病,但不治疗溃疡性结肠炎或回肠克罗恩病,并且可能预防术后克罗恩病的复发。某些益生菌种类可减少溃疡性结肠炎和慢性袋炎的复发,并延迟袋炎的发作。
正常的非致病性肠道细菌在免疫调节、细菌清除或黏膜屏障功能有缺陷的遗传易感宿主中诱导并使慢性肠道炎症持续存在。使用抗生素、益生菌和益生元改变共生细菌的组成并减少其黏膜黏附/侵袭,有可能预防和治疗克罗恩病、袋炎,甚至可能预防和治疗溃疡性结肠炎,但尚未确定最佳治疗方法。